Species Reactivity Human
Clone demcizumab
Source/Isotype Human IgG2 (S377A,delta447K), Kappa
Application /
Specificity Detects DLL4
Gene DLL4
Other Names Delta4
Gene ID 54567 (Human)
Background Demcizumab (dancizumab, OMP-21M18) is a humanized monoclonal antibody (IGG2) developed by OncoMed Pharmaceuticals, targeting DLL4(Delta-like ligand 4) , which belongs to the Notch signaling pathway inhibitor. The core mechanism is the inhibition of the Notch pathway by blocking the binding of DLL4 to NOTCH1/4 receptors, and the inhibition of the Notch signaling pathway by the DLL4-like ligand, induction of tumorigenic “Non-functional angiogenesis”(vascular endothelial hyperproliferation but lack of intact lumen and blood flow perfusion, aggravating tumor hypoxia) and reduction of tumor stem cell (CSCs) frequency, while potentially modulating the immune microenvironment.
Storage Store at 2-8℃ short term (1-2 weeks).Store at ≤ -20℃ long term. Avoid repeated freeze-thaw.
Formulation Supplied as a 0.2 μm filtered solution of PBS, pH7.2-7.4.
Endotoxin < 1 EU/mg, determined by LAL gel clotting assay
